Seitz W, Kärcher K H, Binder W
University Clinic for Radiotherapy and Radiobiology Vienna, Austria.
Semin Surg Oncol. 1988;4(2):100-2.
Modern oncological treatment of metastatic renal cell carcinoma may have different goals: first of all, improvement of survival rates; secondly, elimination of symptoms like pain from osseous lesions or disorders of central nervous system functions. Chemotherapy or radiotherapy or the combination of both should improve life quality and be tolerable to the patient. Close interdisciplinary contacts of medical and radiological oncologists are therefore necessary. Radiotherapy should be carried out under conditions of high-voltage energy and modern treatment planning to concentrate and limit the irradiation volume as much as possible. Split-course technique and radiation as interval treatment between chemotherapy courses seem to be optimal. Our clinical results indicate that the reported radioresistance of renal cell carcinoma might result from radiobiological and methodological misinterpretations.
首先是提高生存率;其次是消除诸如骨病变引起的疼痛或中枢神经系统功能障碍等症状。化疗或放疗或两者联合应改善生活质量且患者可耐受。因此,医学肿瘤学家和放射肿瘤学家之间密切的跨学科联系是必要的。放疗应在高电压能量和现代治疗计划条件下进行,以尽可能集中和限制照射体积。分段治疗技术以及作为化疗疗程之间间隔治疗的放疗似乎是最佳的。我们的临床结果表明,所报道的肾细胞癌放射抗性可能源于放射生物学和方法学上的误解。